厄贝沙坦联合螺内酯对慢性心力衰竭患者血清脑钠肽及C-反应蛋白的影响  

Effects of irbesartan and spironolactone intervention on serum brain natriuretic peptide and high-sensitivity C-reactive protein in patients with chronic heart failure

作　　者：胡欢[1] 邓云霞[1] 

机构地区：[1]湖北潜江江汉油田总医院内二科,湖北潜江433124

出　　处：《海南医学院学报》2014年第2期191-194,共4页Journal of Hainan Medical University

基　　金：浙江省乐清市科技计划(2010Y010)~~

摘　　要：目的:评价厄贝沙坦联合螺内酯对慢性心力衰竭患者血清脑钠肽(brain natriuretic peptide,BNP)及超敏C反应蛋白(high-sensitivity C-reactive protein,hs-CRP)的影响。方法:68例慢性心力衰竭患者,随机分成两组,观察组和对照组,各34例。对照组:给予常规的治疗方案进行治疗。观察组:在常规治疗方案的基础上,加用厄贝沙坦片及螺内酯片。结果:实施治疗后,所有患者的心功能情况均得到改善,且观察组的各项指标都优于对照组。治疗后,两组血清BNP水平均降低,差异具有统计学意义(P<0.01),且此时观察组血清BNP水平为(1.74±0.48)ng/mL低于对照组血清BNP水平(2.53±0.61)ng/mL,差异有统计学意义(P<0.01)。治疗后,两组血清hs-CRP水平均降低,且此时观察组血清hs-CRP水平为(6.73±0.96)μg/mL低于对照组血清hs-CRP水平(8.92±1.05)μg/mL,差异均具有统计学意义(P<0.01)。结论:厄贝沙坦联合螺内酯治疗慢性心力衰竭疗效显著,并可以明显改善患者的血清BNP及hs-CRP水平。Objective. To investigate effects of irbesartan and spironolactone intervention on serum brain natriuretic peptide （BNP） and high-sensitivity C-reactive protein （hs-CRP） in patients with chronic heart failure. Method.A total of 68 chronic heart failure patients were randomly divided into observation group and the control group with 34 cases in each group. Both groups were treated with conventional treat- ments while observation group was also given irbesartan tablets and spironolactone tablets. Results：After the treatments, heart functions of all patients were improved, relative indicators of the observation group was significant superior to that of the control group. After the treatment, the serum level of BNP of the

关 键 词：厄贝沙坦 螺内酯 慢性心力衰竭 脑钠肽 超敏C反应蛋白 

分 类 号：R541[医药卫生—心血管疾病]